EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Mark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W Sayaman, Derrick Renner, Ekaterina Kalashnikova, Gillian L Hirst, Christina Yau, Denise M Wolf, Wen Li, Amy L Delson, Smita Asare und 19 weitere

Cancer Cell · 2023-06 · 41 (6) · 1091-1102.e4

DOI: 10.1016/j.ccell.2023.04.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2023-06. Verfasst von Mark Jesus M Magbanua und 30 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: mark.magbanua@ucsf.edu. Hauptthemen laut MEDLINE: Breast Neoplasms, Triple Negative Breast Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 201-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHGRI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment via non-invasive tumor burden assessment. To investigate subtype-specific differences in the clinical significance and biology of ctDNA shedding, we perform serial personalized ctDNA analysis in hormone receptor (HR)-positive/HER2-negative breast cancer and triple-negative breast cancer (TNBC) patients receiving neoadjuvant chemotherapy (NAC) in the I-SPY2 trial. ctDNA positivity rates before, during, and after NAC are higher in TNBC than in HR-positive/HER2-negative breast cancer patients. Early clearance of ctDNA 3 weeks after treatment initiation predicts a favorable response to NAC in TNBC only. Whereas ctDNA positivity associates with reduced distant recurrence-free survival in both subtypes. Conversely, ctDNA negativity after NAC correlates with improved outcomes, even in patients with extensive residual cancer. Pretreatment tumor mRNA profiling reveals associations between ctDNA shedding and cell cycle and immune-associated signaling. On the basis of these findings, the I-SPY2 trial will prospectively test ctDNA for utility in redirecting therapy to improve response and prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTriple Negative Breast NeoplasmsCirculating Tumor DNAHumansFemaleNeoadjuvant TherapyClinical RelevanceAntineoplastic Combined Chemotherapy ProtocolsBiologyErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

circulating tumor DNAgene expressionneoadjuvant chemotherapypathologic complete responsereceptor subtyperesidual cancer burden

Substanzen

Circulating Tumor DNAErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: mark.magbanua@ucsf.edu.
  • University of California, San Francisco, San Francisco, CA 94143, USA.
  • Natera, Inc., Austin, TX 78753, USA.
  • UCSF Breast Science Advocacy Core, San Francisco, CA 94143, USA.
  • Quantum Leap Healthcare Collaborative, San Francisco, CA 94118, USA.
  • Natera, Inc., Austin, TX 78753, USA; Mayo Clinic, Rochester, MN 55905, USA.

Förderung

  • NCI NIH HHS
  • NHGRI NIH HHS
  • NIGMS NIH HHS
  • California Breast Cancer Research Program
  • Stand Up To Cancer
  • Natera Inc
  • National Institutes of Health
  • National Human Genome Research Institute

Zitieren

APA

Magbanua, M. J. M., Brown Swigart, L., Ahmed, Z., Sayaman, R. W., Renner, D., Kalashnikova, E., Hirst, G. L., Yau, C., Wolf, D. M., Li, W., Delson, A. L., Asare, S., Liu, M. C., Albain, K., Chien, A. J., Forero-Torres, A., Isaacs, C., Nanda, R., Tripathy, D., …, & van 't Veer, L. J. (2023). Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell, 41(6), 1091-1102.e4. https://doi.org/10.1016/j.ccell.2023.04.008

Vancouver

Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;41(6):1091-1102.e4. doi:10.1016/j.ccell.2023.04.008

BibTeX
@article{Magbanua2023,
  author = {Magbanua, Mark Jesus M and Brown Swigart, Lamorna and Ahmed, Ziad and Sayaman, Rosalyn W and Renner, Derrick and Kalashnikova, Ekaterina and Hirst, Gillian L and Yau, Christina and Wolf, Denise M and Li, Wen and Delson, Amy L and Asare, Smita and Liu, Minetta C and Albain, Kathy and Chien, A Jo and Forero-Torres, Andres and Isaacs, Claudine and Nanda, Rita and Tripathy, Debu and Rodriguez, Angel and Sethi, Himanshu and Aleshin, Alexey and Rabinowitz, Matthew and Perlmutter, Jane and Symmans, W Fraser and Yee, Douglas and Hylton, Nola M and Esserman, Laura J and DeMichele, Angela M and Rugo, Hope S and van 't Veer, Laura J},
  title = {Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy},
  journal = {Cancer Cell},
  year = {2023},
  volume = {41},
  number = {6},
  pages = {1091--1102.e4},
  doi = {10.1016/j.ccell.2023.04.008}
}
Kostenlos starten →